Actively Recruiting
Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Led by National Society for Neurosonology and Cerebral Circulation · Updated on 2026-04-13
336
Participants Needed
1
Research Sites
379 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
CONDITIONS
Official Title
Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-85 years
- Diagnosis of acute ischemic stroke eligible for thrombolytic therapy
- Planned or completed thrombolytic therapy with non-immunogenic staphylokinase
You will not qualify if you...
- Known intolerance or hypersensitivity to recombinant proteins containing staphylokinase
- Contraindications to thrombolytic therapy for ischemic stroke
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze
Saint Petersburg, Russia
Actively Recruiting
Research Team
T
Tatiana Kharitonova
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here